Narrow search
Showing 1 - 10 of 56,422
Cover Image
Baseline Assessment of an Inner City Population Enrolled in an Asthma Disease Management Programme: Data for Continuous Programme Improvement
Maljanian, Rose; Goethe, John W.; Wolf, Scott A.; … - In: Disease Management and Health Outcomes 5 (1999) 3, pp. 135-143
management programme for asthma and presents the results of a study of patients referred to this programme. The objectives of the …-reported asthma triggers; and 4. patients' self-care skills. The proportion of referred patients who actually enrolled in the … asthma in inner city and minority patients, which are important topics in current research. …
Persistent link: https://www.econbiz.de/10005590086
Cover Image
Inhaled Fluticasone Propionate: A Pharmacoeconomic Review of its Use in the Management of Asthma
Lamb, Harriet M.; Culy, Christine R.; Faulds, Diana - In: PharmacoEconomics 18 (2000) 5, pp. 487-510
Contemporary asthma management guidelines list inhaled corticosteroids as the preferred controller medication for … patients with persistent asthma. Despite the availability of explicit guidelines, there is evidence that these agents are … for the treatment of asthma. Like other agents of its class, its efficacy is backed by extensive clinical data. More …
Persistent link: https://www.econbiz.de/10005404779
Cover Image
Changes in Antipsychotic Medication Use after Implementation of a Medicaid Mental Health Carve-Out in the US
Robst, John - In: PharmacoEconomics 30 (2012) 5, pp. 387-396
Background:Background: Many Medicaid programmes now offer behavioural healthcare through managed care organizations. Medicaid programmes are concerned about carve-outs because the use of non-included services may rise, limiting the efficiencies anticipated with the implementation of managed...
Persistent link: https://www.econbiz.de/10010541093
Cover Image
Angiotensin Converting Enzyme (ACE) Inhibitors and Heart Failure: The Consequences of Underprescribing
Andersson, Fredrik; Cline, Charles; Ryden-Bergsten, Tina; … - In: PharmacoEconomics 15 (1999) 6, pp. 535-550
prescribing an ACE inhibitor varies, and clinical trials have included different categories of patients; it is inappropriate to …
Persistent link: https://www.econbiz.de/10005449042
Cover Image
Under-Utilisation of beta-Blockers After Acute Myocardial Infarction: Pharmacoeconomic Implications
Bradford, W. David; Chen, Jersey; Krumholz, Harlan M. - In: PharmacoEconomics 15 (1999) 3, pp. 257-268
We reviewed the literature on the efficacy and effectiveness of beta-blocker therapy and examined the economic consequences of under-utilisation. Despite the literature documenting the value of beta-blockers, the therapy is not prescribed at the appropriate rates. Approximately half of acute...
Persistent link: https://www.econbiz.de/10005243162
Cover Image
Trends in Outpatient Prescription Drug Use and Related Costs in the US: 1998-2003
Wysowski, Diane K.; Governale, Laura A.; Swann, Joslyn - In: PharmacoEconomics 24 (2006) 3, pp. 233-236
Objective: To present a brief synopsis of trends in the number of prescriptions and retail costs of outpatient drugs dispensed in the US between 1998 and 2003. Methods: Data were extracted from IMS Health, the National Prescription Audit Plus(TM) and the National Disease and Therapeutic...
Persistent link: https://www.econbiz.de/10005243221
Cover Image
Pharmacoeconomic Consequences of Variable Patient Compliance With Prescribed Drug Regimens
Urquhart, John - In: PharmacoEconomics 15 (1999) 3, pp. 217-228
Variable compliance with prescribed drug regimens is a leading source of variability in drug response. Specifics differ by drug and disease. The role of variable compliance was clearly defined in 2 trials of lipid-lowering agents, cholestyramine and gemfibrozil, in which exceptionally careful...
Persistent link: https://www.econbiz.de/10005404784
Cover Image
Cost Effectiveness of Fluticasone Propionate Plus Salmeterol Versus Fluticasone Propionate Plus Montelukast in the Treatment of Persistent Asthma
OConnor, Richard D.; Nelson, Harold; Borker, Rohit; … - In: PharmacoEconomics 22 (2004) 12, pp. 815-825
Background: Asthma is a chronic disease, the two main components of which are inflammation and bronchoconstriction …. Fluticasone propionate (FP) and salmeterol, a strategy that treats both main components of asthma, has been recently compared with …. Objective: To determine the relative cost effectiveness when persistent asthma is treated with FP/salmeterol 100/50mug twice …
Persistent link: https://www.econbiz.de/10005007607
Cover Image
Analysis of Asthma-Related Costs and Patterns of Resource Utilization in a Managed-Care Population
Armstrong, Edward P.; Krueger, Kem; Langley, Paul C. - In: Disease Management and Health Outcomes 9 (2001) 3, pp. 161-171
Objectives: To identify the asthma prevalence rate, the total healthcare and asthma-related treatment costs, and the … medical and pharmacy costs associated with different asthma medication usage patterns in a managed-care organisation (MCO … claims database was searched from 1994 to 1996 for patients having at least one asthma medical claim in either the first or …
Persistent link: https://www.econbiz.de/10005590104
Cover Image
A Comparison of a Budesonide-Based and a Beclomethasone/Prednisolone-Based Management Strategy for the Treatment of Severe Asthma in General Practice
Mohan, Govindaraj; MacLusky, Kevin A.; Godley, Clifford C. - In: Disease Management and Health Outcomes 5 (1999) 2, pp. 83-91
Objective: Patients with severe asthma often require short courses of oral corticosteroids in addition to their daily … the treatment of severe asthma. A budesonide-based management strategy and a beclomethasone/prednisolone-based management … daily via Turbohaler(R) with 2mg twice daily nebulised budesonide for 7 to 14 days on asthma exacerbation, or a …
Persistent link: https://www.econbiz.de/10005590120